While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage ...

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed ...

Eli Lilly (LLY) reported $15.56 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 37.6%. EPS of $6.31 for the same period compares to $3.92 a year ago. The ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight management.

Eli Lilly's pill works in a similar way to Wegovy, Ozempic, and Novo Nordisk's diabetes pill Rybelsus, targeting a gut hormone called GLP-1 to suppress a person's appetite and regulate blood sugar.

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...